|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 498/04 | (2006.01) |
| A61P 5/24 | (2006.01) | ||
| A61K 31/5383 | (2006.01) | ||
| A61K 9/08 | (2006.01) | ||
| A61K 9/48 | (2006.01) | ||
| A61K 47/14 | (2017.01) | ||
| A61P 25/00 | (2006.01) |
| (11) | Number of the document | 3765024 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19711866.4 |
| Date of filing the European patent application | 2019-03-13 | |
| (97) | Date of publication of the European application | 2021-01-20 |
| (45) | Date of publication and mention of the grant of the patent | 2023-11-22 |
| (46) | Date of publication of the claims translation | 2024-02-26 |
| (86) | Number | PCT/EP2019/056303 |
| Date | 2019-03-13 |
| (87) | Number | WO 2019/175253 |
| Date | 2019-09-19 |
| (30) | Number | Date | Country code |
| 201862642622 P | 2018-03-14 | US |
| (72) |
TROWER, Mike , GB
KERR, Mary , GB
ELDER, David , GB
LAZARO, Monica , US
BUSH, Derek , US
|
| (73) |
KaNDy Therapeutics Limited ,
400 South Oak Way, Reading, Berkshire RG2 6AD,
GB
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Nauja farmacinė vaisto forma, apimanti dvigubo NK-1/NK-3 receptoriaus antagonistus |
| NOVEL PHARMACEUTICAL FORMULATION COMPRISING DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS |
| Payment date | Validity (years) | Amount | |
| 2025-02-24 | 7 | 162.00 EUR |
| 2026-03-13 |